Recent advances in first-pass radionuclide angiography.
First-pass RNA has been in use for more than 20 years for both the diagnosis and prognosis of coronary, congenital, valvular, and pulmonary heart disease. Recent advances in gamma-camera and computer technology have made first-pass RNA easier to acquire, more accurate, and faster to process. It stands out as the best technology available for the investigation of short-duration phenomena, including peak exercise, that affect the left and right ventricles. Perhaps most importantly, the introduction of the technetium-based myocardial perfusion imaging agent, sestamibi, has made it possible to combine all of the measurements of regional and global ventricular function and volume obtainable from first-pass data with high-resolution tomographic myocardial perfusion imaging, thus providing the most comprehensive noninvasive evaluation available of the patient with known or suspected coronary disease.
University of Wisconsin Medical School, Laboratory of Nuclear Cardiology, Milwaukee Heart Institute.
S C
SC
Port
D003327:Coronary Disease / Q000000981:diagnostic imaging*; D005080:Exercise Test; D015637:Gated Blood-Pool Imaging; D006331:Heart Diseases / Q000000981:diagnostic imaging; D006801:Humans; D015899:Tomography, Emission-Computed, Single-Photon; D015646:Ventriculography, First-Pass